NASDAQ
ALXO

Alx Oncology Holdings 

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Alx Oncology Holdings  Stock Price

Vitals

Today's Low:
$4.7
Today's High:
$5.0691
Open Price:
$4.73
52W Low:
$5.82
52W High:
$20.4
Prev. Close:
$4.61
Volume:
1071572

Company Statistics

Market Cap.:
$255.94 million
Book Value:
7.042
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$107000
Profit Margin:
0%
Return on Assets TTM:
-21.55%
Return on Equity TTM:
-36.07%

Company Profile

Alx Oncology Holdings  had its IPO on 2020-07-17 under the ticker symbol ALXO.

The company operates in the Healthcare sector and Biotechnology industry. Alx Oncology Holdings  has a staff strength of 55 employees.

Stock update

Shares of Alx Oncology Holdings  opened at $4.73 at the start of the last trading session i.e. 2023-03-21.

The stocks traded within a range of $4.7 - $5.07, and closed at $4.81.

This is a +4.34% increase from the previous day's closing price.

A total volume of 1,071,572 shares were traded at the close of the day’s session.

In the last one week, shares of Alx Oncology Holdings  have slipped by -14.56%.

Alx Oncology Holdings 's Key Ratios

Alx Oncology Holdings  has a market cap of $255.94 million, indicating a price to book ratio of 1.5268 and a price to sales ratio of 5906.2383.

In the last 12-months Alx Oncology Holdings ’s revenue was $0 with a gross profit of $107000 and an EBITDA of $-123418000. The EBITDA ratio measures Alx Oncology Holdings 's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Alx Oncology Holdings ’s operating margin was 0% while its return on assets stood at -21.55% with a return of equity of -36.07%.

In Q3, Alx Oncology Holdings ’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Alx Oncology Holdings ’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.92 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alx Oncology Holdings ’s profitability.

Alx Oncology Holdings  stock is trading at a EV to sales ratio of 4254.356 and a EV to EBITDA ratio of -1.2958. Its price to sales ratio in the trailing 12-months stood at 5906.2383.

Alx Oncology Holdings  stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$317.69 million
Total Liabilities
$25.24 million
Operating Cash Flow
$13.70 million
Capital Expenditure
$1.04 million
Dividend Payout Ratio
0%

Alx Oncology Holdings  ended 2023 with $317.69 million in total assets and $0 in total liabilities. Its intangible assets were valued at $317.69 million while shareholder equity stood at $286.96 million.

Alx Oncology Holdings  ended 2023 with $0 in deferred long-term liabilities, $25.24 million in other current liabilities, 41000.00 in common stock, $-294758000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $49.05 million and cash and short-term investments were $284.91 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Alx Oncology Holdings ’s total current assets stands at $290.81 million while long-term investments were $8.22 million and short-term investments were $235.86 million. Its net receivables were $700000.00 compared to accounts payable of $5.88 million and inventory worth $0.

In 2023, Alx Oncology Holdings 's operating cash flow was $13.70 million while its capital expenditure stood at $1.04 million.

Comparatively, Alx Oncology Holdings  paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
$4.81
52-Week High
$20.4
52-Week Low
$5.82
Analyst Target Price
$33.43

Alx Oncology Holdings  stock is currently trading at $4.81 per share. It touched a 52-week high of $20.4 and a 52-week low of $20.4. Analysts tracking the stock have a 12-month average target price of $33.43.

Its 50-day moving average was $7.84 and 200-day moving average was $10.13 The short ratio stood at 25.87 indicating a short percent outstanding of 0%.

Around 257% of the company’s stock are held by insiders while 10165.7% are held by institutions.

Frequently Asked Questions About Alx Oncology Holdings 

The stock symbol (also called stock or share ticker) of Alx Oncology Holdings  is ALXO

The IPO of Alx Oncology Holdings  took place on 2020-07-17

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Ouster Inc. (OUST-WT)
$0.12
-0.01
-7.69%
$218.1
2.23
+1.03%
$1.84
0
+0.25%
$146.97
3.07
+2.13%
$10.78
-0.01
-0.09%
$2.48
-0.02
-0.8%
$13.86
0.31
+2.29%
$0.02
-0
-12.61%
Aviva plc (AIVAF)
$5.28
-0.04
-0.75%

Most Active

Last Price
Chg
Chg%
$15.77
3.59
+29.47%
$0.14
0.01
+8.46%
$0.97
0.03
+2.99%
$0.22
0.13
+153.78%
Tesla Inc (TSLA)
$197.58
14.33
+7.82%

Top Gainers

Last Price
Chg
Chg%
$0
0
+58723.53%
$0
0
+20460.42%
$0.63
0
+2548.22%
$0.02
0
+1566.67%
PICCW (PICCW)
$0.05
0.05
+900%

Top Losers

Last Price
Chg
Chg%
NGC-WT (NGC-WT)
$0
-0.04
-94.66%
$4.7
-33.3
-87.63%
Imara Inc (IMRA)
$21
0
-78.71%
$0.09
-0.29
-76.97%

About

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin’s lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company’s pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Address

323 Allerton Avenue, South San Francisco, CA, United States, 94080